Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 330


MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer.

Ling XH, Han ZD, Xia D, He HC, Jiang FN, Lin ZY, Fu X, Deng YH, Dai QS, Cai C, Chen JH, Liang YX, Zhong WD, Wu CL.

Mol Biol Rep. 2014 May;41(5):2779-88. doi: 10.1007/s11033-014-3132-7. Epub 2014 Jan 23.


MicroRNA-335 acts as a candidate tumor suppressor in prostate cancer.

Xiong SW, Lin TX, Xu KW, Dong W, Ling XH, Jiang FN, Chen G, Zhong WD, Huang J.

Pathol Oncol Res. 2013 Jul;19(3):529-37. doi: 10.1007/s12253-013-9613-5. Epub 2013 Mar 3.


Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy.

Sun X, Liu Z, Yang Z, Xiao L, Wang F, He Y, Su P, Wang J, Jing B.

Diagn Pathol. 2013 Dec 18;8:208. doi: 10.1186/1746-1596-8-208.


Dysregulated microRNA-224/apelin axis associated with aggressive progression and poor prognosis in patients with prostate cancer.

Wan Y, Zeng ZC, Xi M, Wan S, Hua W, Liu YL, Zhou YL, Luo HW, Jiang FN, Zhong WD.

Hum Pathol. 2015 Feb;46(2):295-303. doi: 10.1016/j.humpath.2014.10.027. Epub 2014 Nov 26.


MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1.

Lin ZY, Huang YQ, Zhang YQ, Han ZD, He HC, Ling XH, Fu X, Dai QS, Cai C, Chen JH, Liang YX, Jiang FN, Zhong WD, Wang F, Wu CL.

Int J Cancer. 2014 Aug 1;135(3):541-50. doi: 10.1002/ijc.28707. Epub 2014 Jan 10.


Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.

Xu S, Yi XM, Zhou WQ, Cheng W, Ge JP, Zhang ZY.

Int J Clin Exp Pathol. 2015 Nov 1;8(11):14335-44. eCollection 2015.


Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer.

Chiyomaru T, Yamamura S, Fukuhara S, Hidaka H, Majid S, Saini S, Arora S, Deng G, Shahryari V, Chang I, Tanaka Y, Tabatabai ZL, Enokida H, Seki N, Nakagawa M, Dahiya R.

PLoS One. 2013;8(3):e58929. doi: 10.1371/journal.pone.0058929. Epub 2013 Mar 12.


Expression of SOCSs in human prostate cancer and their association in prognosis.

Zhu JG, Dai QS, Han ZD, He HC, Mo RJ, Chen G, Chen YF, Wu YD, Yang SB, Jiang FN, Chen WH, Sun ZL, Zhong WD.

Mol Cell Biochem. 2013 Sep;381(1-2):51-9. doi: 10.1007/s11010-013-1687-6. Epub 2013 May 11.


Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy.

Zeng X, Hu Z, Wang Z, Tao J, Lu T, Yang C, Lee B, Ye Z.

Prostate Cancer Prostatic Dis. 2014 Jun;17(2):119-25. doi: 10.1038/pcan.2013.51. Epub 2014 Jan 14.


MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer.

Yang B, Liu Z, Ning H, Zhang K, Pan D, Ding K, Huang W, Kang XL, Wang Y, Chen X.

Cancer Biomark. 2016 Jul 8;17(2):223-30. doi: 10.3233/CBM-160634.


Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.

Sun X, Yang Z, Zhang Y, He J, Wang F, Su P, Han J, Song Z, Fei Y.

Int J Clin Exp Pathol. 2015 Jul 1;8(7):8394-401. eCollection 2015.


The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients.

Avgeris M, Stravodimos K, Fragoulis EG, Scorilas A.

Br J Cancer. 2013 Jun 25;108(12):2573-81. doi: 10.1038/bjc.2013.250. Epub 2013 May 23.


Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer.

Fuse M, Kojima S, Enokida H, Chiyomaru T, Yoshino H, Nohata N, Kinoshita T, Sakamoto S, Naya Y, Nakagawa M, Ichikawa T, Seki N.

J Hum Genet. 2012 Nov 26;57(11):691-9. doi: 10.1038/jhg.2012.95. Epub 2012 Aug 2.


SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial-mesenchymal transition in vitro.

Wang L, Zhang J, Yang X, Chang YW, Qi M, Zhou Z, Zhang J, Han B.

Prostate Cancer Prostatic Dis. 2013 Dec;16(4):301-7. doi: 10.1038/pcan.2013.25. Epub 2013 Aug 6.


MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.

Lin ZY, Chen G, Zhang YQ, He HC, Liang YX, Ye JH, Liang YK, Mo RJ, Lu JM, Zhuo YJ, Zheng Y, Jiang FN, Han ZD, Wu SL, Zhong WD, Wu CL.

Mol Cancer. 2017 Feb 27;16(1):48. doi: 10.1186/s12943-017-0615-x.


miR-152 controls migration and invasive potential by targeting TGFα in prostate cancer cell lines.

Zhu C, Li J, Ding Q, Cheng G, Zhou H, Tao L, Cai H, Li P, Cao Q, Ju X, Meng X, Qin C, Hua L, Shao P, Yin C.

Prostate. 2013 Jul;73(10):1082-9. doi: 10.1002/pros.22656. Epub 2013 Mar 4.


miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth.

Wang N, Li Q, Feng NH, Cheng G, Guan ZL, Wang Y, Qin C, Yin CJ, Hua LX.

Asian J Androl. 2013 Nov;15(6):735-41. doi: 10.1038/aja.2013.80. Epub 2013 Aug 26.


Stromal expression of MiR-21 predicts biochemical failure in prostate cancer patients with Gleason score 6.

Melbø-Jørgensen C, Ness N, Andersen S, Valkov A, Dønnem T, Al-Saad S, Kiselev Y, Berg T, Nordby Y, Bremnes RM, Busund LT, Richardsen E.

PLoS One. 2014 Nov 17;9(11):e113039. doi: 10.1371/journal.pone.0113039. eCollection 2014.


Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.

Zhang L, Guo F, Gao X, Wu Y.

Mol Med Rep. 2015 Jul;12(1):1298-304. doi: 10.3892/mmr.2015.3455. Epub 2015 Mar 9.


Supplemental Content

Support Center